The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is the strongest signal yet that curcumin can meaningfully reduce osteoarthritis pain, backed by 11 studies with a moderate effect size and no harmful results — but the high variability across trials means the exact benefit for any given person remains uncertain.
This is among the first meta-analyses to suggest vitamin E may help prevent COPD onset, but the same analysis found no benefit for preventing death from COPD, and the evidence base is still thin — treat it as promising but preliminary.
This analysis suggests that the belief vitamin D prevents severe COVID-19 is likely built on small, flattering studies that got published because they were positive — the bigger, more reliable trials saw nothing.
This is the first pooled analysis of its kind, but the apparent benefit is contested because aloe vera failed to outperform sodium bicarbonate or benzydamine, meaning it may not be a clear upgrade over existing options.
This single study suggests L-arginine may be unexpectedly effective at helping small kidney stones pass, but it tested only 162 hospitalized patients, and its failure to reduce pain or analgesic use means the real-world advantage might be narrower than the headline rate suggests.
This meta-analysis offers some of the strongest evidence yet that vitamin D may help regulate immune activity in systemic lupus, but the benefit has only been shown in people with the condition, and the ideal dose is unknown.
This is one of the first broad looks at this specific probiotic for social symptoms in autism, so the finding is intriguing but far from settled — the review itself calls the overall evidence limited and heterogeneous.
This is one of the first reviews to focus on L-citrulline specifically in this population, so the finding is novel but narrow: the blood pressure effect is promising, yet the same review found no significant improvements in arterial stiffness, muscle strength, or metabolic markers, meaning the benefit may be limited to one outcome in a specific group.
This is the first systematic review on jiaogulan for blood sugar control, so the result is promising but far from settled; one analysis can’t tell us whether the effect holds across different doses, longer time frames, or more diverse populations.
This is early, striking evidence that adding curcumin to standard chemo may meaningfully shrink tumors and extend time without progression, but the lack of blinding and small size mean the real effect is likely smaller than these dramatic numbers suggest — more trials are needed before this becomes a recommendation.
This finding adds early, moderately consistent evidence for taurine's effect on blood fats, but the high statistical disagreement between studies means the exact size of the benefit is still uncertain, and the results come from a clinical population that may not reflect a general healthy reader.
This is a moderate-sized signal from 5 studies in 572 people, but three found a benefit while two found none, so the overall evidence is real but not bulletproof.
This is early evidence from one network meta-analysis, so while it suggests vitamin E may help slow bone loss, it's not yet a settled recommendation — the dose and long-term effects remain unclear.
This finding is surprising because manganese is a necessary nutrient, yet here it's associated with harm; but the evidence is still early — this is among the first systematic reviews on this pairing — and the same study found no effect on other growth measures, so the picture is far from settled.
This is among the first meta-analyses on vitamin D for ovarian reserve, and while it found no overall benefit, the substantial heterogeneity in the studies means the question isn't settled — treat the null result as a strong caution, not the final word.
This is a single, unblinded trial in a hospital setting, so while the effect was large and statistically significant, the result needs replication before it applies to everyday use — treat it as an intriguing signal, not settled science.
This is the first large RCT on peony for oral lichen planus, and the effect is unusually large (53.9% vs. 34.4% complete response), but because neither patients nor doctors knew who got the supplement, the real-world benefit could be smaller — and the results only apply to people with this specific, hard-to-treat condition.
This is an unusually large effect from a systematic review of 688 patients, but it's among the first indexed studies on vitamin K for this specific use, so the finding needs replication before you'd act on it.
This small, 6‑month trial suggests Lactobacillus acidophilus may help children whose epilepsy hasn’t responded to standard drugs, but with only 60 participants and no replication yet, the finding is intriguing rather than actionable for the general public.
This is a striking early signal for a novel probiotic delivery route, but it comes from a single study — so treat the size of the effect as promising, not settled.
This is one of the first rigorous trials to link prenatal B12 dose size to infant neurodevelopment, but with no placebo group and a single, specific population (vegetarian mothers), the finding is promising but far from settled.
This pilot study suggests that training status, not just baseline deficiency, may determine how much vitamin D3 you need to raise your levels — a useful reminder that one-size-fits-all dosing advice may miss the mark, though the small sample and short duration mean the pattern is far from settled.
This is one of the first systematic looks at vitamin D for TB prevention, and its clear null finding contests the idea that supplementation meaningfully protects against infection — but because the body of evidence is still small, the picture is far from settled.
This single RCT challenges the popular notion that NAC is a reliable protector against kidney damage from contrast dye, but with only 120 patients and a specific Egyptian clinical population, the picture is far from settled — treat this as a provocative data point, not a verdict.
This small, short study found a surprisingly strong effect on one specific blood pressure number, but it’s the first of its kind, and none of the other cardiometabolic markers budged — so the picture is intriguing but far from conclusive.
This is the first solid evidence for saffron on blood pressure in this clinical group, but because it's a single, early meta-analysis with a modest effect that wasn't mirrored in other key outcomes, the finding should be seen as intriguing but far from proven.
This null result challenges the common assumption that vitamin E can slow or reverse ataxia in Friedreich's disease, but the evidence is moderate-certainty and based on only 513 participants across seven studies — so the picture is contested, not settled.
This is one of the first systematic reviews on NAC for alcohol craving, and its null result challenges the popular notion that NAC is a reliable anti-craving supplement — but the picture is far from settled, since the same analysis hinted at a possible effect on PTSD symptoms that deserves further study.
This isn't a breakthrough — it's a provocative signal from a small, low-certainty evidence base that leaves the overall picture genuinely mixed.
This is the first meta-analysis to directly compare before versus after exercise protein timing for strength, and while it found a modest benefit for leg press, the effect was borderline significant and didn't replicate across chest press or lean mass gains — so it's intriguing, but too early to rewrite your routine around it.